Hemostatic Drugs Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Hemostatic Drugs. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Hemostatic Drugs Indian Medical PG Question 1: Warfarin's mechanism of action is
- A. Inhibiting Vitamin K dependent carboxylation (Correct Answer)
- B. Chelating calcium ions
- C. Inhibiting antithrombin III activity
- D. Inhibiting thrombin activity
Hemostatic Drugs Explanation: ***Inhibiting Vitamin K dependent carboxylation***
- **Warfarin** acts as an antagonist to **vitamin K**, competitively inhibiting the enzyme **vitamin K epoxide reductase**.
- This prevents the **gamma-carboxylation** of vitamin K-dependent clotting factors (II, VII, IX, X, and proteins C and S), rendering them biologically inactive.
*Chelating calcium ions*
- **Calcium ions** are essential cofactors in the coagulation cascade, but warfarin does not directly affect their concentration or chelate them.
- Anticoagulants that chelate calcium, such as **citrate**, are typically used *in vitro* (e.g., in blood collection tubes), not systemically.
*Inhibiting antithrombin III activity*
- This mechanism describes the action of **heparin** and its derivatives, which enhance the natural anticoagulant activity of **antithrombin III**.
- Warfarin's primary action is on vitamin K metabolism, not on antithrombin III potentiation.
*Inhibiting thrombin activity*
- Direct thrombin inhibitors (**DTIs**), such as dabigatran and argatroban, directly bind to and inhibit the activity of **thrombin (factor IIa)**.
- Warfarin's action is upstream in the coagulation cascade, affecting the synthesis of multiple clotting factors, including prothrombin (the precursor to thrombin).
Hemostatic Drugs Indian Medical PG Question 2: A 20-year-old woman with a family history of von Willebrand disease is found to have an activated partial thromboplastin time (aPTT) of 78 (normal = 32) on routine testing prior to cholecystectomy. Further investigation reveals a prothrombin time (PT) of 13 (normal = 12), a platelet count of 350,000/mm³, and an abnormal bleeding time. Which of the following should be administered in the perioperative period?
- A. Factor VIII
- B. Desmopressin (DDAVP) (Correct Answer)
- C. Platelets
- D. Vitamin K
Hemostatic Drugs Explanation: ***Desmopressin (DDAVP)***
- **Desmopressin** is the first-line treatment for **von Willebrand disease (vWD)** [1], especially for type 1, which this patient's profile suggests (prolonged aPTT, normal PT, normal platelet count, and abnormal bleeding time).
- It works by stimulating the release of endogenous **von Willebrand factor (vWF)** and **factor VIII** from endothelial cells [1].
*Factor VIII*
- While Factor VIII deficiency can cause prolonged aPTT, this patient's presentation with a family history of **vWD**, normal PT, and abnormal bleeding time points specifically to a **vWF** defect rather than isolated **Factor VIII** deficiency [1].
- Administration of direct **Factor VIII** is not the primary treatment for **vWD**, although vWF concentrate (which contains Factor VIII) may be used for severe cases [1].
*Platelets*
- The patient's **platelet count is normal** (350,000/mm³), indicating that a platelet transfusion is not necessary.
- **vWD** is a disorder of platelet adhesion, not a problem with platelet quantity.
*Vitamin K*
- **Vitamin K** is essential for the synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S.
- A deficiency in **Vitamin K** typically results in a prolonged **PT** [2], which is normal in this patient.
Hemostatic Drugs Indian Medical PG Question 3: Ximelagatran is used as ?
- A. Anticoagulant (Correct Answer)
- B. Fibrinolytic
- C. Platelet inhibitor
- D. Clot buster
Hemostatic Drugs Explanation: ***Anticoagulant***
- Ximelagatran is a **direct thrombin inhibitor**, meaning it directly blocks the action of thrombin, a key enzyme in the coagulation cascade.
- By inhibiting thrombin, it prevents the formation of **fibrin clots**, thus acting as an anticoagulant.
*Platelet inhibitor*
- **Platelet inhibitors** prevent platelets from clumping together to form a clot, often by targeting pathways like ADP receptors or COX-1 enzyme.
- Examples include **aspirin** and **clopidogrel**, which have different mechanisms of action than Ximelagatran.
*Clot buster*
- **Clot busters** are also known as thrombolytic agents, which actively dissolve existing blood clots.
- They work by activating **plasminogen** to produce plasmin, an enzyme that breaks down fibrin.
*Fibrinolytic*
- **Fibrinolytics** are a class of drugs that enhance **fibrinolysis**, the natural process of breaking down blood clots.
- **Thrombolytics** are a subset of fibrinolytic drugs used therapeutically to dissolve clots.
Hemostatic Drugs Indian Medical PG Question 4: A 16-year-old adolescent boy with a history of severe hemophilia A is undergoing an elective inguinal hernia repair. Which of the following is the best option for preventing or treating a bleeding complication in the setting of this disease?
- A. Combination of desmopressin and fresh-frozen plasma
- B. Factor IX concentrate
- C. Fresh-frozen plasma
- D. Combination of ε-aminocaproic acid and desmopressin (Correct Answer)
Hemostatic Drugs Explanation: ***Combination of ε-aminocaproic acid and desmopressin***
- For **mild hemophilia A**, **desmopressin** can aid in increasing factor VIII levels temporarily [1]. **ε-aminocaproic acid (EACA)** is an **antifibrinolytic agent** which is useful for mucosal bleeding conditions or as an adjunct during dental procedures or minor surgeries to prevent clot breakdown.
- While desmopressin alone may not fully prevent surgical bleeding in hemophilia A, the addition of EACA helps stabilize the clot, reducing the risk of bleeding for minor surgical procedures like inguinal hernia repair [1].
*Combination of desmopressin and fresh-frozen plasma*
- **Desmopressin** is useful for **mild hemophilia A** as it releases stored factor VIII [1]. **Fresh-frozen plasma (FFP)** provides all clotting factors.
- Using FFP carries a higher risk of **volume overload** and **transfusion-related acute lung injury (TRALI)** compared to factor concentrates or desmopressin alone.
*Factor IX concentrate*
- **Factor IX concentrate** is used to treat **hemophilia B**, which is a deficiency in factor IX, not factor VIII.
- Administering factor IX concentrate to a patient with hemophilia A would not correct their coagulation defect or prevent bleeding [1].
*Fresh-frozen plasma*
- While **fresh-frozen plasma (FFP)** contains factor VIII, it is in **non-concentrated amounts**, making it less effective for severe hemophilia A.
- FFP also carries a risk of transfusion reactions and **volume overload**, especially when large quantities are needed.
Hemostatic Drugs Indian Medical PG Question 5: Polyglactin 910 suture material ("Vicryl") is a / an
- A. Absorbable natural suture
- B. Non-absorbable synthetic suture
- C. Non-absorbable natural suture
- D. Absorbable synthetic suture (Correct Answer)
Hemostatic Drugs Explanation: ***Absorbable synthetic suture***
- **Polyglactin 910**, marketed as **Vicryl**, is a **synthetic copolymer** of glycolide and lactide that undergoes hydrolysis in the body.
- This hydrolysis leads to its eventual reabsorption over 56-70 days, classifying it as an **absorbable** material.
- Vicryl maintains tensile strength for approximately 21 days before being fully absorbed.
*Absorbable natural suture*
- Natural absorbable sutures, such as **catgut** (plain and chromic), are derived from animal tissues and are absorbed enzymatically within the body.
- **Polyglactin 910** is **synthetic**, not natural, despite being absorbable.
*Non-absorbable synthetic suture*
- Non-absorbable synthetic sutures (e.g., **nylon**, **polypropylene**, **polyester**) retain their tensile strength and remain in the body indefinitely or require removal.
- Vicryl is designed to be **absorbed** over time through hydrolysis, distinguishing it from non-absorbable types.
*Non-absorbable natural suture*
- Examples of non-absorbable natural sutures include **silk** and **cotton**, which are derived from natural sources and are not reabsorbed by the body.
- Polyglactin 910 is both **synthetic** and **absorbable**, making this option incorrect.
Hemostatic Drugs Indian Medical PG Question 6: Following injury to a blood vessel, immediate hemostasis is achieved by:
- A. Fibrin deposition
- B. Vasoconstriction (Correct Answer)
- C. Platelet adhesion
- D. Thrombosis
Hemostatic Drugs Explanation: ***Vasoconstriction***
- Following blood vessel injury, **vasoconstriction** occurs immediately, reducing blood flow and minimizing blood loss.
- It is a **reflex response** mediated by local factors and neural mechanisms aiming to maintain hemostasis.
*Fibrin deposition*
- **Fibrin deposition** occurs later in the hemostatic process, primarily during the **coagulation phase** after initial vascular responses.
- It is not an immediate response; rather, it's part of the **clot stabilization** process, requiring activation of the clotting cascade.
*Thrombosis*
- Thrombosis refers to the formation of a **blood clot** within a vessel, which happens after initial hemostatic mechanisms are activated.
- It is not the **immediate** response post-injury; there is a sequence of events that lead to thrombosis after vasoconstriction and platelet activation.
*Platelet adhesion*
- Although platelet adhesion is crucial in hemostasis, it occurs following **vasoconstriction** and is not an immediate response to vessel injury [1][2].
- This process is part of the **primary hemostasis** phase, which cannot occur efficiently without prior initial vasoconstriction.
**References:**
[1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 581-582.
[2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.
Hemostatic Drugs Indian Medical PG Question 7: A 34-year-old woman has Raynaud's phenomenon associated with systemic sclerosis (scleroderma). Which of the following is the most appropriate management for this condition?
- A. ergotamine
- B. calcium channel blockers (nifedipine)
- C. beta-blocking drugs
- D. warm clothing (Correct Answer)
Hemostatic Drugs Explanation: ***Warm clothing***
- Maintaining **core body temperature** and direct protection of extremities from **cold exposure** is the primary non-pharmacological management for Raynaud's phenomenon.
- This helps prevent the **vasospasm** triggered by cold, reducing the frequency and severity of attacks.
*ergotamine*
- **Ergotamine** is a powerful **vasoconstrictor** and would worsen Raynaud's phenomenon by further narrowing blood vessels.
- It is primarily used for **migraine treatment** and is contraindicated in conditions involving vasoconstriction.
*calcium channel blockers (nifedipine)*
- While **calcium channel blockers** like nifedipine are often used as **second-line pharmacological treatment** for Raynaud's, warm clothing represents a more fundamental and universally applicable management strategy. [1]
- Nifedipine works by causing **vasodilation**, which can reduce the severity and frequency of attacks when non-pharmacological methods are insufficient. [1]
*beta-blocking drugs*
- **Beta-blockers** can worsen Raynaud's phenomenon by causing **vasoconstriction** due to unopposed alpha-adrenergic activity. [1]
- These drugs are generally **contraindicated** in patients with Raynaud's syndrome. [1]
Hemostatic Drugs Indian Medical PG Question 8: The following drugs are effective in the management of menorrhagia except :
- A. Progestational agents
- B. Prostaglandins (Correct Answer)
- C. Non-steroidal anti-inflammatory drugs
- D. Anti-fibrinolytic drugs
Hemostatic Drugs Explanation: ***Prostaglandins***
- Prostaglandins, particularly **PGE2** and **PGF2α**, are generally associated with **increased uterine contractions** and **vasodilation**, which can worsen menstrual bleeding rather than reduce it.
- While cyclooxygenase inhibitors (NSAIDs) work by inhibiting prostaglandin synthesis, exogenous prostaglandins themselves are not used to treat menorrhagia and can exacerbate it.
*Progestational agents*
- Progestins help to **stabilize the endometrium**, reducing excessive bleeding by inducing decidualization and limiting endometrial growth.
- They can be administered orally, via injection, or through an **intrauterine device (IUD)** like the levonorgestrel-releasing IUD (Mirena), which is highly effective.
*Non-steroidal anti-inflammatory drugs*
- NSAIDs reduce menorrhagia by **inhibiting prostaglandin synthesis** in the endometrium, which leads to reduced vasodilation and uterine contractions.
- They also help alleviate associated **dysmenorrhea** (menstrual pain).
*Anti-fibrinolytic drugs*
- These drugs, such as **tranexamic acid**, work by **inhibiting plasminogen activation**, thereby preventing the breakdown of fibrin clots within the uterus.
- This promotes clot stability and reduces menstrual blood loss significantly.
Hemostatic Drugs Indian Medical PG Question 9: In the treatment of undiagnosed megaloblastic anemia, vitamin B12 and folic acid should be given together because:
- A. Vitamin B12 acts as a cofactor for dihydrofolate reductase.
- B. Folic acid alone causes improvement of anemic symptoms but neurological dysfunction continues. (Correct Answer)
- C. Vitamin B12 deficiency may result in methylfolate trap.
- D. Folic acid is required for conversion of methylmalonyl CoA to succinyl CoA.
Hemostatic Drugs Explanation: In megaloblastic anemia, it is critical to differentiate between Vitamin B12 and Folic acid deficiency before starting monotherapy.
### **Explanation of the Correct Answer**
**Option B** is correct because folic acid can "mask" a Vitamin B12 deficiency. Both nutrients are required for DNA synthesis; giving large doses of folic acid can bypass the metabolic block in the folate cycle, thereby correcting the megaloblastic anemia (hematological symptoms). However, Vitamin B12 is uniquely required for the conversion of methylmalonyl-CoA to succinyl-CoA, a process essential for myelin sheath integrity. If B12 deficiency is treated with folic acid alone, the **neurological degeneration (Subacute Combined Degeneration of the spinal cord)** will continue to progress and may become irreversible.
### **Analysis of Incorrect Options**
* **Option A:** Vitamin B12 is not a cofactor for dihydrofolate reductase (DHFR); DHFR is the enzyme that reduces dietary folate/dihydrofolate into the active tetrahydrofolate (THF).
* **Option C:** While the **"Methylfolate Trap"** is a real phenomenon (where B12 deficiency traps folate in the N5-methyl THF form), this explains *why* B12 deficiency causes anemia, not the clinical danger of giving folic acid alone.
* **Option D:** This is factually reversed. **Vitamin B12** (as deoxyadenosylcobalamin), not folic acid, is the essential cofactor for the conversion of methylmalonyl-CoA to succinyl-CoA.
### **High-Yield NEET-PG Pearls**
* **The Trap:** In B12 deficiency, folate is "trapped" as methyl-THF because the enzyme *Methionine Synthase* (which requires B12) cannot convert it back to THF.
* **Neurological triad:** B12 deficiency affects the posterior columns (vibration/position loss), corticospinal tracts (spasticity), and spinocerebellar tracts.
* **Rule of Thumb:** Never treat megaloblastic anemia with folic acid alone until B12 deficiency is ruled out. Always supplement both if the diagnosis is uncertain.
Hemostatic Drugs Indian Medical PG Question 10: A drug that binds to and inhibits Gp IIb/IIIa glycoprotein and is responsible for platelet antiaggregatory effects is:
- A. Clopidogrel
- B. Enoxaparin
- C. Fondaparinux
- D. Tirofiban (Correct Answer)
Hemostatic Drugs Explanation: **Explanation:**
The correct answer is **Tirofiban**.
**1. Why Tirofiban is correct:**
Glycoprotein (Gp) IIb/IIIa is a receptor found on the surface of platelets. When activated, it binds to fibrinogen, acting as a "bridge" that links platelets together, leading to platelet aggregation (the final common pathway of platelet activation). **Tirofiban** is a non-peptide, reversible antagonist that binds specifically to these receptors, preventing fibrinogen binding and thus inhibiting platelet aggregation. It is primarily used in Acute Coronary Syndromes (ACS) and during Percutaneous Coronary Intervention (PCI).
**2. Why the other options are incorrect:**
* **Clopidogrel:** This is a P2Y12 receptor antagonist. It works by inhibiting the ADP-induced pathway of platelet activation, not by directly binding to Gp IIb/IIIa.
* **Enoxaparin:** This is a Low Molecular Weight Heparin (LMWH). It acts as an anticoagulant by accelerating the activity of Antithrombin III, primarily inhibiting Factor Xa and, to a lesser extent, Factor IIa (Thrombin).
* **Fondaparinux:** This is a synthetic pentasaccharide that acts as a selective Factor Xa inhibitor. It has no direct effect on platelet receptors.
**3. High-Yield Clinical Pearls for NEET-PG:**
* **Gp IIb/IIIa Inhibitors:** Remember the trio: **Abciximab** (monoclonal antibody), **Eptifibatide** (cyclic peptide), and **Tirofiban** (non-peptide).
* **Abciximab** is unique because its binding is irreversible and it can also bind to the vitronectin receptor.
* **Glanzmann Thrombasthenia:** This is a congenital bleeding disorder caused by a deficiency or dysfunction of the Gp IIb/IIIa receptor.
* **Side Effect:** The most significant side effect of Gp IIb/IIIa inhibitors is bleeding and acute thrombocytopenia.
More Hemostatic Drugs Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
